Sign in
Enrolling by invitationNo phase

Follows pregnant people with obesity who take Wegovy, and their babies

Observes safety outcomes in pregnant people with obesity who took semaglutide.

Key facts

Who runs it
Novo Nordisk A/S
Where
Princeton, United StatesSee the siteAlso in 2 other countries, 2 sites
Trial code
Registry title
A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
Status
Enrolling by invitation
People taking part
728 people, planned
Started
5 Jul 2023
Expected to end
30 Dec 2032
Type of study
Observational, 2 groups
Record updated
14 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women who are or recently were pregnant and have obesity or overweight. One group took Wegovy in pregnancy; the other did not.

Age
15 to 50 years
Sex
Women only
Disease stage
Obesity or overweight with at least one weight-related health condition
Earlier treatment
Wegovy group: took at least one dose of Wegovy during pregnancy. Comparison group: no Wegovy or other GLP-1 RA during pregnancy.

Main reasons for not taking part

  • Mental incapacity, unwillingness or language barriers that prevent understanding or cooperation
  • Comparison group: used Wegovy or another GLP-1 RA at any time during pregnancy

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Signed consent obtained before any study-related activities
  • Female 15-50 years of age at the time of signing consent
  • Currently or recently pregnant
  • Resident of country included in the study
  • Authorisation for her HCP(s) to provide data to the registry
  • Exposed to Wegovy cohort: Exposure to at least one dose of Wegovy at any time during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition
  • Unexposed to Wegovy cohort: Have obesity or overweight with at least one weight related comorbid condition at conception

Who cannot take part

  • Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation
  • Unexposed to Wegovy cohort: Exposure to Wegovy or other GLP-1 RA at any time during pregnancy

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 15 and 50 years old?

Where in United States

Also in 2 other countries, 2 sites

  • Princeton, New JerseyHospital not named in the registryEnrolling by invitation

About the trial

What the trial wants to find out

This is an observational, prospective Wegovy (semaglutide 2.4 milligram [mg]) Pregnancy Registry Study. The aim of this study is to compare the maternal, foetal, and infant outcomes of pregnant women who are exposed to Wegovy during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition with outcomes in an internal comparison cohort of pregnant women with obesity or overweight with at least one weight related comorbid condition at conception and who are not exposed to Wegovy or other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) during pregnancy. Infant outcomes will be assessed throughout the infant's first year of life, with active data collection by the registry occurring at 4 and 12 months after delivery.

The 2 groups in the trial

  • Participants Exposed to Wegovy

    Pregnant women who are exposed to Wegovy at any time during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition will be observed in this prospective observational study.

  • Participants Unexposed to Wegovy or Other GLP-1 RAs

    Pregnant women who have overweight with at least one weight-related comorbid condition or who have obesity at conception and who are not exposed to Wegovy or other GLP-1 RAs at any time during pregnancy but who may be exposed to other products for weight management will be observed in this prospective observational study.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Wegovy® (Semaglutide 2.4 mg) Pregnancy Registry Study: A Prospective Cohort Study to Investigate Safety Outcomes of Exposure to Wegovy During Pregnancy
Plain-language title
Follows pregnant people with obesity who take Wegovy, and their babiesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05872022, who can take part
Record updated
14 January 2026